 Precision BioSciences Inc NASDAQ: DTIL has announced three-year follow-up data showing long-term stable reduction of low-density lipoprotein LDL cholesterol levels in nonhuman primates NHPs after in vivo gene editing of the PCSK9 gene with its ARCUS platform. The company published the data online in Molecular Therapy. 